Temsirolimus

Renal cell carcinoma is a highly prevalent malignant tumor of the urinary system. Patients with advanced renal cell carcinoma have insufficient sensitivity to traditional radiotherapy and chemotherapy, and targeted therapy has become the core clinical regimen for this population. Temsirolimus is a specific mTOR inhibitor. By blocking the mammalian target of rapamycin signaling pathway, it inhibits tumor cell proliferation, arrests cell cycle progression and reduces neovascularization. It is the first targeted drug approved for the treatment of advanced metastatic renal cell carcinoma with poor prognosis, and can also be used as the second-line treatment for mantle cell lymphoma, providing a low-toxicity and effective option for elderly patients or patients with underlying comorbidities who cannot tolerate other potent therapies.

The global temsirolimus market size was approximately USD 210 million in 2023, and the compound annual growth rate from 2024 to 2030 is expected to remain at around 3.2%. The growth momentum mainly comes from the improvement of the diagnosis and treatment rate of urinary system tumors and the expansion of combination therapy regimens. At present, the original research product still occupies the major global market share. There are no approved generic drugs in China yet, and only a small number of enterprises are in the stage of API R&D and declaration. The overall market competition pattern is relatively relaxed, and the advancement of relevant generic drug R&D pipelines is expected to further reduce the medication cost for patients.

The original research enterprise of temsirolimus is Pfizer, and the original trade name is Torisel. Its core compound patent in the United States expired in 2017, and its compound patent in China also expired in 2018. The main dosage form approved for the original product is injection, with a specification of 25mg/mL. It has been included in the FDA Reference Listed Drug Catalog, but has not yet been included in the China Listed Drug Catalog. Up to now, no enterprise in China has obtained the A-status registration number of temsirolimus API, and no generic preparation of this variety has been approved for marketing. (Data as of October 2025, please refer to the official website of CDE for the latest information)

In response to the R&D and quality control needs of temsirolimus, CATO can provide a full set of impurity reference standards for this API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. All products comply with the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, which can effectively shorten the methodology validation cycle of R&D enterprises and provide reliable material basis support for the declaration process.